The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Cellular Therapy Option for Treatment of Central Nervous System EBV-PTLD

Susan Prockop, MD
Published Online:8:09 PM, Tue March 19, 2019


Susan Prockop, MD, associate attending in pediatrics at Memorial Sloan Kettering Cancer Center, discusses an option available for the treatment of central nervous system (CNS) Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).

According to a subset analysis, patients are at very high risk of developing this disease after hematopoietic stem cell transplant or solid organ transplant and the modalities available are still limited, Prockop says. A high dose of radiation can be debilitating with significant side effects, so adoptive immunotherapy with EBV-specific T cells is a good option for these patients.

In addition, this subset analysis speaks more to the biology of this therapy and its ability to deal with EBV-PTLD in the CNS.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.